The Symptoms Of Multiple Sclerosis Blog

Information and Resources on Multiple Sclerosis and its signs and symptoms!
English flagItalian flagKorean flagChinese (Simplified) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flagRussian flagGreek flagDutch flagBulgarian flagCzech flagCroat flagDanish flagFinnish flagHindi flagPolish flagRumanian flagSwedish flagNorwegian flag
By N2H

Nutra Pharma Announces Initial Positive Safety Data From Clinical Study In Adrenomyeloneuropathy (AMN) August 18, 2008

Filed under: MS — The Symptoms Of Multiple Sclerosis Blog @ 7:00 am

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported initial positive safety data from its Phase IIb/IIIa clinical study of RPI-78M for treating Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm’s leading drug candidate for treating neurological and autoimmune disorders.

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • StumbleUpon
  • Technorati


add to del.icio.usPrint This Post Print This Post

Leave a Reply